FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

PANACEABIO

201
+201 (0%)
Updated 02:30 21/09 IST

PANACEABIO Buy or Sell - FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for PANACEABIO
Disclaimer
0% Bullish
0% Bearish

PANACEABIO Buy or Sell - Brokerage Reports

No. of reports in last year
0
No. of analysts
0
Average Consensus Forecast
Consensus Potential
0.00%
See PANACEABIO Share Price Targets >>

PANACEABIO Ratings

Long term PANACEABIO rating by FrontPage users
0/5 (0 Ratings)0
Find answers to all your questions on live PANACEABIO message board: Is PANACEABIO buy or sell? Should I buy PANACEABIO shares? Why are PANACEABIO shares falling? Should I invest in PANACEABIO stock?

  1. Home
  2. PANACEABIO Forum

PANACEABIO Share Price Discussion


US FDA ISSUES WARNING LETTER TO PANACEA BIOTEC's BADDI FACILITY
Like
Reply
M
Reputation: 10,169 • Yesterday 3:10 AM

Type
Buy
Instrument
SILVER 04DEC20 FUT
Entry Price
₹60,710
Price@Trade
₹60,840
Target Price
₹61,490
Stop Price
₹60,500
Valid Till
Dec 4, 2020 11:20 AM
Margin
₹985,995 approx for 90 Qty
Status
Waiting for entry
Like
Reply

EU MAY IMPOSE TARIFFS ON STAINLESS STEEL FROM INDIA , INDONESIA. EU OPENS PROBE IN TO ALLEGED STEEL DUMPING FROM INDIAN COs
Like
Reply

RAMCO SYSTEMS GOT MULTI-COUNTRY PAYROLL SERVICES ORDER
Like
Reply

SJVN GOT 100 MW SOLAR PROJECT IN GUJARAT
Like
Reply
S
Reputation: -207 • Yesterday 3:08 AM

Type
Sell
Instrument
CRUDEOIL 19OCT20 FUT
Entry Price
₹2,931
Price@Trade
₹2,936
Target Price
₹2,900
Stop Price
₹2,940
Valid Till
Sep 30, 2020 11:20 AM
Margin
₹293,870 approx for 100 Qty
Status
Waiting for entry
Like
Reply
G
Reputation: -10,627 • Yesterday 3:07 AM

Type
Buy
Instrument
SILVER 04DEC20 FUT
Entry Price
₹60,950
Price@Trade
₹60,954
Target Price
₹61,700
Stop Price
₹60,500
Valid Till
Sep 30, 2020 11:20 AM
Margin
₹657,285 approx for 60 Qty
Status
Active
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Yesterday 3:08 AM

Update
Trade Entered
Entry Price
₹60,950
M
Reputation: 10,169 • Yesterday 3:05 AM

Type
Buy
Instrument
NATURALGAS 27OCT20 FUT
Entry Price
₹186.1
Price@Trade
₹186.6
Target Price
₹190.9
Stop Price
₹185
Valid Till
Oct 27, 2020 11:20 AM
Margin
₹866,650 approx for 20000 Qty
Status
Exited before entry
Like
Reply (1)
See all replies
Mrc The Boss @Mrc
Yesterday 3:09 AM

Update
Exited before entry
Price @ Update
₹186.4
PROFIT LEVEL MINER in MCX-CRUDEOIL
Now trail stop @ cost zone And relax nothing g...

MCX:CRUDEOIL - 1400688
Target intact
Only for u guys
Told u to stay at the correct levels
Trying to always in d right side of market🙏🙏🙏
Hit the like for more updates
Which encourages us more
1
Reply
U
Reputation: 61,266 • Yesterday 3:05 AM

Type
Buy
Instrument
NATURALGAS 27OCT20 FUT
Entry Price
₹186.6
Price@Trade
₹186.6
Target Price
₹195
Stop Price
₹180
Valid Till
Oct 1, 2020 11:20 AM
Margin
₹2,166,625 approx for 50000 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
CRUDEOIL 19OCT20 FUT
Entry Price
₹2,936
Price@Trade
₹2,936
Target Price
₹2,967
Stop Price
₹2,910
Valid Till
Sep 30, 2020 11:20 AM
Margin
₹293,870 approx for 100 Qty
Status
Active
Like
Reply
M
Reputation: 10,169 • Yesterday 3:03 AM

Type
Sell
Instrument
NATURALGAS 27OCT20 FUT
Entry Price
₹187.4  ₹186.8
Price@Trade
₹186.7
Target Price
₹182
Stop Price
₹190
Valid Till
Oct 27, 2020 11:20 AM
Margin
₹866,675 approx for 20000 Qty
Status
Exited
Exit Price
₹186.5
Net P&L
+₹6,000 (+0.69%)
Like
Reply (3)
See all replies
Mrc The Boss @Mrc
Yesterday 3:03 AM

Update
Entry Price Modified
Price @ Update
₹186.8
Original Entry Price
₹187.4
New Entry Price
₹186.8
TrackerBot @trackerbot
Yesterday 3:04 AM

Update
Trade Entered
Entry Price
₹186.8
Mrc The Boss @Mrc
Yesterday 3:05 AM

Update
Exited
Exit Price
₹186.5
Net P&L
+₹6,000 (+0.69%)
N
Reputation: 6,300 • Yesterday 3:03 AM
RBI excludes 6 PSBs from Second Schedule of RBI Act
A bank mentioned in the Second Schedule of the Reserve Bank of India Act is known as 'Scheduled Commercial Bank'. These six banks merged with other public sector banks (PSBs) with effect from April 1.
Moneycontrol
Like
Reply
S
Reputation: 2,464 • Yesterday 3:02 AM

Type
Buy
Instrument
SILVERM 30NOV20 FUT
Entry Price
₹60,944
Price@Trade
₹60,944
Target Price
₹61,400
Stop Price
₹60,750
Valid Till
Sep 30, 2020 11:20 AM
Margin
₹54,419.81 approx for 5 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
COPPER 30OCT20 FUT
Entry Price
₹524.75
Price@Trade
₹524.75
Target Price
₹530
Stop Price
₹523
Valid Till
Sep 30, 2020 11:20 AM
Margin
₹485,593.75 approx for 10000 Qty
Status
Active
Like
Reply

TCS - 1400673

BUY ABOVE 2505

OR

SELL BELOW 2460
Like
Reply

Type
Sell
Instrument
CRUDEOIL 19OCT20 FUT
Entry Price
₹2,938
Price@Trade
₹2,938
Target Price
₹2,920
Stop Price
₹2,950
Valid Till
Sep 30, 2020 11:20 AM
Margin
₹293,871.25 approx for 100 Qty
Status
Active
Like
Reply
M
Reputation: 10,169 • Yesterday 3:00 AM

Type
Buy
Instrument
NATURALGAS 27OCT20 FUT
Entry Price
₹186.6
Price@Trade
₹186.5
Target Price
₹190.9
Stop Price
₹185
Valid Till
Oct 27, 2020 11:20 AM
Margin
₹866,575 approx for 20000 Qty
Status
Exited
Exit Price
₹187.1
Net P&L
+₹10,000 (+1.15%)
Like
Reply (2)
See all replies
TrackerBot @trackerbot
Yesterday 3:01 AM

Update
Trade Entered
Entry Price
₹186.6
Mrc The Boss @Mrc
Yesterday 3:02 AM

Update
Exited
Exit Price
₹187.1
Net P&L
+₹10,000 (+1.15%)
M
Reputation: 10,169 • Yesterday 2:59 AM

Type
Buy
Instrument
NATURALGAS 27OCT20 FUT
Entry Price
₹186.6
Price@Trade
₹186.6
Target Price
₹189.9
Stop Price
₹185
Valid Till
Oct 27, 2020 11:20 AM
Margin
₹866,675 approx for 20000 Qty
Status
Exited
Exit Price
₹186.6
Net P&L
₹0 (0%)
Like
Reply (1)
See all replies
Mrc The Boss @Mrc
Yesterday 2:59 AM

Update
Exited
Exit Price
₹186.6
Net P&L
₹0 (0%)
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • PANACEABIO - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization1,214.97
    Enterprise Value1,365.11
    Price to Earnings656.61
    Price to Book Value2.91
    Return on Capital Employed0.03
    Return on Equity-0.19
    Face Value1
    Dividend YieldNA
  • PANACEABIO - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    27-Nov-17Rudra Shares & Stocks BrokersBuy310
    PANACEABIO Brokerage Price Target
  • PANACEABIO Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Sep 21201201201201
    Sep 18216.4223.25205.05207.1
    Sep 17201.3220.8200.2213.55
    Sep 16193.45208193200.95
    Sep 15193197.35191191.8
  • PANACEABIO Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹193.63
    30 Day Moving Average₹192.98
    50 Day Moving Average₹196.89
    100 Day Moving Average₹187.02
    200 Day Moving Average₹155.58
  • PANACEABIO - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue577530.090.09
    Operating Profit8223.492.49
    Profit Before Tax-61-83.78-0.27
    Net Income-72-86.25-0.17
  • PANACEABIO - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds4183780.11
    Total Liabilities1,0241,482-0.31
    Total Assets1,4421,860-0.22
  • PANACEABIO - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity172115.860.48
    Cash from Investing Activity-3-32.18-0.91
    Cash from Financing Activity-164-87.20.88
    Net Cash Flow6-3.52-2.7
  • PANACEABIO - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets-0.04-0.05
    Return on Equity-0.19-1.27
    Return on Capital Employed0.030.02
  • PANACEABIO - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue-0.15
    3 Year CAGR Growth in Operating Profit0.21
    3 Year CAGR Growth in EBIDTA0.04
    3 Year CAGR Growth in Net Income-0.1
    3 Yr CAGR Growth - Diluted EPS-0.1
  • PANACEABIO - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue-0.03
    5 Year CAGR Growth in Operating Profit1.98
    5 Year CAGR Growth in EBIDTA2.61
    5 Year CAGR Growth in Net Income0.69
    3 Yr CAGR Growth - Diluted EPS0.69
  • PANACEABIO - Recent News

    keyboard_arrow_down
    NewsBot
    Yesterday 10:51 AM
    Pharma company Panacea Biotec gets warning letter from USFDA for Baddi facility
    The Economic Times
    NewsBot
    Sep 24 9:51 AM
    Panacea Biotec completes Phase I/II study of DengiAlI vaccine
    The Economic Times
    NewsBot
    Sep 24 6:23 AM
    Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study
    Moneycontrol
    NewsBot
    Jul 19 9:01 AM
    Seven Indian pharmaceutical companies race to develop vaccine for deadly coronavirus
    The Economic Times
    NewsBot
    Jul 8 10:33 AM
    Panacea Biotec aims to make 1 billion doses of COVID-19 vaccine candidate in 2022
    Moneycontrol
    NewsBot
    Jun 15 12:43 PM
    Expect COVID-19 vaccine to enter phase-1 human trial by October: Panacea Biotec's Rajesh Jain
    Moneycontrol
    NewsBot
    Jun 10 6:31 AM
    Panacea Biotec shares zoom 20% on collaboration with US-based Refana to develop COVID-19 vaccine
    The Economic Times
    NewsBot
    Jun 10 6:28 AM
    Panacea joins hands with Ireland's Refana to develop COVID-19 vaccine by early next year
    Moneycontrol
    NewsBot
    Jun 10 6:16 AM
    Panacea Biotec joins hands with US-based Refana to develop COVID-19 vaccine
    The Economic Times
    NewsBot
    Aug 16, 2019 9:18 AM
    Panacea Biotec Q1 loss narrows to Rs 28.27 cr
    moneycontrol.com
  • PANACEABIO - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020